
Mario Thevis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3130706/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol. Drug Testing and Analysis, 2023, 15, 163-172.	2.6	10
2	Risk of unintentional antidoping rule violations by consumption of hemp products. Drug Testing and Analysis, 2023, 15, 27-41.	2.6	5
3	Investigations in carbon isotope ratios of seized testosterone and boldenone preparations. Drug Testing and Analysis, 2022, 14, 514-518.	2.6	6
4	First use of the antiâ€VWF nanobody caplacizumab to treat iTTP in pregnancy. British Journal of Haematology, 2022, 196, .	2.5	17
5	Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 649-659.	3.6	9
6	Urinary phenylethylamine metabolites as potential markers for sports drug testing purposes. Biomedical Chromatography, 2022, 36, e5274.	1.7	4
7	Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes. Analytical and Bioanalytical Chemistry, 2022, 414, 1151-1162.	3.7	12
8	Annual bannedâ€substance review: Analytical approaches in human sports drug testing 2020/2021. Drug Testing and Analysis, 2022, 14, 7-30.	2.6	17
9	Probing for factors influencing exhaled breath drug testing in sports— Pilot studies focusing on the tested individual's tobacco smoking habit and sex. Rapid Communications in Mass Spectrometry, 2022, 36, e9262.	1.5	4
10	Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry. Metabolites, 2022, 12, 146.	2.9	3
11	Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches. Analytica Chimica Acta, 2022, 1202, 339661.	5.4	7
12	Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models. Forensic Toxicology, 2022, 40, 244-262.	2.4	3
13	Probing for the presence of semenogelin in human urine by immunological and chromatographicâ€mass spectrometric methods in the context of sports drug testing. Analytical Science Advances, 2022, 3, 21-28.	2.8	7
14	Stereoisomers in sports drug testing: Analytical strategies and applications. Journal of Chromatography A, 2022, 1674, 463154.	3.7	4
15	Analysis of dried blood spots is a feasible alternative for detecting ephedrine in doping control. Drug Testing and Analysis, 2022, 14, 1685-1695.	2.6	4
16	Investigations on the <i>in vivo</i> metabolism of 5αâ€androstâ€2â€enâ€17â€one. Rapid Communications in Spectrometry, 2022, 36, .	Mass 1.5	2
17	Determination and enantioselective separation of zilpaterol in human urine after mimicking consumption of contaminated meat using highâ€performance liquid chromatography with tandem mass spectrometry techniques. Rapid Communications in Mass Spectrometry, 2022, 36, .	1.5	4
18	Annual bannedâ€substance review: Analytical approaches in human sports drug testing 2019/2020. Drug Testing and Analysis, 2021, 13, 8-35.	2.6	22

#	Article	IF	CITATIONS
19	An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. Drug Testing and Analysis, 2021, 13, 916-928.	2.6	8
20	Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. Drug Testing and Analysis, 2021, 13, 539-549.	2.6	18
21	Probing for the presence of doping agents in exhaled breath using chromatographic/mass spectrometric approaches. Rapid Communications in Mass Spectrometry, 2021, 35, e8939.	1.5	9
22	Investigation of Equine In Vivo and In Vitro Derived Metabolites of the Selective Androgen Receptor Modulator (SARM) ACP-105 for Improved Doping Control. Metabolites, 2021, 11, 85.	2.9	9
23	Mass spectrometric identification and characterization of urinary metabolites of isopropylnorsynephrine for doping control purposes. Analytical Science Advances, 2021, 2, 334-341.	2.8	4
24	Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes. Biomedical Chromatography, 2021, 35, e5075.	1.7	5
25	Do dried blood spots have the potential to support result management processes in routine sports drug testing?—Part 2: Proactive sampling for followâ€up investigations concerning atypical or adverse analytical findings. Drug Testing and Analysis, 2021, 13, 505-509.	2.6	19
26	Detection of anti‧ARS oVâ€2 antibodies in dried blood spots utilizing manual or automated spot extraction and electrochemiluminescence immunoassay (ECLIA). Analytical Science Advances, 2021, 2, 440.	2.8	4
27	Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	28
28	Facilitated Qualitative Determination of Insulin, Its Synthetic Analogs, and C-Peptide in Human Urine by Means of LC–HRMS. Metabolites, 2021, 11, 309.	2.9	12
29	Current Insights into the Steroidal Module of the Athlete Biological Passport. International Journal of Sports Medicine, 2021, 42, 863-878.	1.7	14
30	Carbon isotope ratios of endogenous steroids found in human serum—method development, validation, and reference population-derived thresholds. Analytical and Bioanalytical Chemistry, 2021, 413, 5655-5667.	3.7	9
31	Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 733-744.	1.3	3
32	Broadening the Horizon of Antidoping Analytical Approaches Using Dried Blood Spots. Clinical Chemistry, 2021, 67, 1041-1043.	3.2	3
33	Stanozololâ€Nâ€glucuronide metabolites in human urine samples as suitable targets in terms of routine antiâ€doping analysis. Drug Testing and Analysis, 2021, 13, 1668-1677.	2.6	10
34	Depletion of clomiphene residues in eggs and muscle after oral administration to laying hens. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2021, 38, 1875-1882.	2.3	6
35	Meldonium residues in milk: A possible scenario for inadvertent doping in sports?. Drug Testing and Analysis, 2021, 13, 1906-1910.	2.6	9
36	Mass spectrometric characterization of urinary hydrafinil metabolites for routine doping control purposes. Drug Testing and Analysis, 2021, 13, 1915-1920.	2.6	5

#	Article	IF	CITATIONS
37	Detection of undeclared doping substances in nutritional supplements in the context of followâ€up investigations concerning adverse analytical findings. Drug Testing and Analysis, 2021, 13, 1911-1914.	2.6	8
38	Organâ€onâ€aâ€chip: Determine feasibility of a human liver microphysiological model to assess longâ€ŧerm steroid metabolites in sports drug testing. Drug Testing and Analysis, 2021, 13, 1921-1928.	2.6	17
39	Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1. Journal of Steroid Biochemistry and Molecular Biology, 2021, 212, 105927.	2.5	0
40	Chromatographicâ€mass spectrometric analysis of the urinary metabolite profile of chlorphenesin observed after dermal application of chlorphenesinâ€containing sunscreen. Rapid Communications in Mass Spectrometry, 2021, 35, e9183.	1.5	8
41	Recent advances in identifying and utilizing metabolites of selected doping agents in human sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114312.	2.8	15
42	Effect of a Single Bout of Aerobic Exercise on Kynurenine Pathway Metabolites and Inflammatory Markers in Prostate Cancer Patients—A Pilot Randomized Controlled Trial. Metabolites, 2021, 11, 4.	2.9	7
43	Determination of ghrelin and desacyl ghrelin in human plasma and urine by means of LC–MS/MS for doping controls. Drug Testing and Analysis, 2021, , .	2.6	3
44	Sensitive detection of testosterone and testosterone prohormone administrations based on urinary concentrations and carbon isotope ratios of androsterone and etiocholanolone. Drug Testing and Analysis, 2021, 13, 1835-1851.	2.6	4
45	Sports drug testing and the athletes' exposome. Drug Testing and Analysis, 2021, 13, 1814-1821.	2.6	27
46	Chiral analysis of selected enantiomeric drugs relevant in doping controls. Journal of Chromatography Open, 2021, 1, 100017.	2.2	4
47	The 39th Manfred Donike workshop on doping analysis. Drug Testing and Analysis, 2021, 13, 1812-1813.	2.6	1
48	Akzidentelle Einnahme von Mifegyne im dritten Trimenster – ein Fallbericht. Zeitschrift Fur Geburtshilfe Und Neonatologie, 2021, 225, .	0.4	0
49	Introduction of a PEGylated EPO conjugate as internal standard for EPO analysis in doping controls. Drug Testing and Analysis, 2021, , .	2.6	3
50	Androgens, sports, and detection strategies for anabolic drug use. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, , 101609.	4.7	6
51	Analytical Approaches in Human Sports Drug Testing: Recent Advances, Challenges, and Solutions. Analytical Chemistry, 2020, 92, 506-523.	6.5	39
52	Solidâ€phase extraction–liquid chromatography–tandem mass spectrometry method for the qualitative analysis of 61 synthetic cannabinoid metabolites in urine. Drug Testing and Analysis, 2020, 12, 27-40.	2.6	17
53	Annual bannedâ€substance review – Analytical approaches in human sports drug testing. Drug Testing and Analysis, 2020, 12, 7-26.	2.6	22
54	Elevated urinary cobalt concentrations identified in routine doping controls can originate from vitamin B ₁₂ . Rapid Communications in Mass Spectrometry, 2020, 34, e8649.	1.5	8

#	Article	IF	CITATIONS
55	Tainted toothpaste – Analytical investigation into an unusual adverse finding. Drug Testing and Analysis, 2020, 12, 570-572.	2.6	6
56	Simplified quantification of insulin, its synthetic analogs and Câ€peptide in human plasma by means of LCâ€HRMS. Drug Testing and Analysis, 2020, 12, 382-390.	2.6	26
57	Fatalities associated with NPS stimulants in the Greater Cologne area. International Journal of Legal Medicine, 2020, 134, 229-241.	2.2	7
58	Identification of metabolites of peptide-derived drugs using an isotope-labeled reporter ion screening strategy. Clinical Chemistry and Laboratory Medicine, 2020, 58, 690-700.	2.3	8
59	Detection of follistatinâ€based inhibitors of the TGFâ€Î² signaling pathways in serum/plasma by means of LCâ€HRMS/MS and Western blotting. Drug Testing and Analysis, 2020, 12, 1636-1648.	2.6	8
60	Sport doping detection in focus: A perspective from Prof. Dr Mario Thevis. Analytical Science Advances, 2020, 1, 141-142.	2.8	0
61	First Steps toward Uncovering Gene Doping with CRISPR/Cas by Identifying SpCas9 in Plasma via HPLC–HRMS/MS. Analytical Chemistry, 2020, 92, 16322-16328.	6.5	13
62	Dietary Supplement and Food Contaminations and Their Implications for Doping Controls. Foods, 2020, 9, 1012.	4.3	74
63	Paper spray mass spectrometry – A potential complementary technique for the detection of polar compounds in sports drug testing. Drug Testing and Analysis, 2020, 12, 1658-1665.	2.6	13
64	Elimination profiles of microdosed ostarine mimicking contaminated products ingestion. Drug Testing and Analysis, 2020, 12, 1570-1580.	2.6	23
65	Implementation of the HIF activator IOXâ€2 in routine doping controls – Pilot study data. Drug Testing and Analysis, 2020, 12, 1614-1619.	2.6	6
66	The 38 th Manfred Donike workshop on doping analysis. Drug Testing and Analysis, 2020, 12, 1541-1542.	2.6	0
67	Analysis of cobalt for human sports drug testing purposes using ICP―and LCâ€ŧCPâ€MS. Drug Testing and Analysis, 2020, 12, 1666-1672.	2.6	15
68	Excretion of 19â€norandrosterone after consumption of boar meat. Drug Testing and Analysis, 2020, 12, 1581-1586.	2.6	7
69	Can dried blood spots (DBS) contribute to conducting comprehensive SARSâ€CoVâ€2 antibody tests?. Drug Testing and Analysis, 2020, 12, 994-997.	2.6	37
70	Singleâ€dose administration of clenbuterol is detectable in dried blood spots. Drug Testing and Analysis, 2020, 12, 1366-1372.	2.6	16
71	Identification of Trenbolone Metabolites Using Hydrogen Isotope Ratio Mass Spectrometry and Liquid Chromatography/High Accuracy/High Resolution Mass Spectrometry for Doping Control Analysis. Frontiers in Chemistry, 2020, 8, 435.	3.6	11
72	Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing?. Drug Testing and Analysis, 2020, 12, 704-710.	2.6	33

#	Article	IF	CITATIONS
73	Detecting the misuse of 7â€oxoâ€DHEA by means of carbon isotope ratio mass spectrometry in doping control analysis. Rapid Communications in Mass Spectrometry, 2020, 34, e8776.	1.5	8
74	Inter-Laboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured Intact by Mass Spectrometry. Clinical Chemistry, 2020, 66, 579-586.	3.2	17
75	Acute hypertrophic but not maximal strength loading transiently enhances the kynurenine pathway towards kynurenic acid. European Journal of Applied Physiology, 2020, 120, 1429-1436.	2.5	13
76	Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS. Analytical and Bioanalytical Chemistry, 2020, 412, 3765-3777.	3.7	40
77	Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training. Exercise Immunology Review, 2020, 26, 24-42.	0.4	31
78	Erythropoietic effects of lowâ€dose cobalt application. Drug Testing and Analysis, 2019, 11, 200-207.	2.6	18
79	Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Science International, 2019, 303, 109925.	2.2	30
80	Implementation and Performance of the Gas Chromatography/Combustion/Isotope Ratio Mass Spectrometry-Based Method for the Confirmatory Analysis of Endogenous Anabolic Steroids during the Rio de Janeiro Olympic and Paralympic Games 2016. Analytical Chemistry, 2019, 91, 11747-11756.	6.5	6
81	Safety, hemodynamic effects, and detection of acute xenon inhalation: rationale for banning xenon from sport. Journal of Applied Physiology, 2019, 127, 1511-1518.	2.5	7
82	Effect of acute and chronic xenon inhalation on erythropoietin, hematological parameters, and athletic performance. Journal of Applied Physiology, 2019, 127, 1503-1510.	2.5	9
83	Development of two complementary LC–HRMS methods for analyzing sotatercept in dried blood spots for doping controls. Bioanalysis, 2019, 11, 923-940.	1.5	16
84	Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation. Current Opinion in Endocrine and Metabolic Research, 2019, 9, 22-27.	1.4	5
85	Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine. Forensic Science International, 2019, 303, 109959.	2.2	14
86	Analysis of endogenous steroids in urine by means of multi-immunoaffinity chromatography and isotope ratio mass spectrometry for sports drug testing. Analytical and Bioanalytical Chemistry, 2019, 411, 7563-7571.	3.7	4
87	Detection of the myostatinâ€neutralizing antibody Domagrozumab in serum by means of Western blotting and LCâ€HRMS. Drug Testing and Analysis, 2019, 11, 1714-1723.	2.6	11
88	Recent advances in the determination of insulins from biological fluids. Advances in Clinical Chemistry, 2019, 93, 115-167.	3.7	22
89	Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. Drug Testing and Analysis, 2019, 11, 1755-1760.	2.6	2
90	Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis. Drug Testing and Analysis, 2019, 11, 1644-1655.	2.6	16

#	Article	IF	CITATIONS
91	In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and Cunninghamella elegans and their detection in urine samples. Analytical and Bioanalytical Chemistry, 2019, 411, 3561-3579.	3.7	15
92	Differing Water Intake and Hydration Status in Three European Countries—A Day-to-Day Analysis. Nutrients, 2019, 11, 773.	4.1	11
93	Does oral fluid contribute to exhaled breath samples collected by means of an electret membrane?. Drug Testing and Analysis, 2019, 11, 1764-1770.	2.6	8
94	The 37th Manfred Donike workshop on doping analysis. Drug Testing and Analysis, 2019, 11, 1587-1588.	2.6	0
95	Detection of black market follistatin 344. Drug Testing and Analysis, 2019, 11, 1675-1697.	2.6	6
96	Is heptaminol a (major) metabolite of octodrine?. Drug Testing and Analysis, 2019, 11, 1761-1763.	2.6	10
97	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. International Journal of Legal Medicine, 2019, 133, 1049-1064.	2.2	8
98	Development of a mass spectrometry based detection method for the mitochondrionâ€derived peptide MOTSâ€c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry, 2019, 33, 371-380.	1.5	16
99	SARCOSYL—PAGE: Optimized Protocols for the Separation and Immunological Detection of PEGylated Proteins. Methods in Molecular Biology, 2019, 1855, 131-149.	0.9	7
100	Annual bannedâ€ s ubstance review: Analytical approaches in human sports drug testing. Drug Testing and Analysis, 2019, 11, 8-26.	2.6	14
101	Organ distribution of 4-MEC, MDPV, methoxetamine and α-PVP: comparison of QuEChERS and SPE. Forensic Toxicology, 2018, 36, 320-333.	2.4	17
102	Analytical challenges in sports drug testing. Analytical and Bioanalytical Chemistry, 2018, 410, 2275-2281.	3.7	12
103	Growth hormone isoformâ€differential massÂspectrometry for doping control purposes. Drug Testing and Analysis, 2018, 10, 938-946.	2.6	9
104	Detection of the Human Antiâ€ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LCâ€HRMS. Proteomics - Clinical Applications, 2018, 12, e1700120.	1.6	12
105	Structural elucidation of major selective androgen receptor modulator (SARM) metabolites for doping control. Organic and Biomolecular Chemistry, 2018, 16, 698-702.	2.8	13
106	Effects of different exercise intensities in the morning on football performance components in the afternoon. German Journal of Exercise and Sport Research, 2018, 48, 235-244.	1.2	4
107	Unambiguous identification and characterization of a longâ€ŧerm human metabolite of dehydrochloromethyltestosterone. Drug Testing and Analysis, 2018, 10, 1244-1250.	2.6	22
108	Detection of SARMs in doping control analysis. Molecular and Cellular Endocrinology, 2018, 464, 34-45.	3.2	59

#	Article	IF	CITATIONS
109	Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation. European Journal of Mass Spectrometry, 2018, 24, 145-156.	1.0	22
110	Equine in vivo -derived metabolites of the SARM LGD-4033 and comparison with human and fungal metabolites. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1074-1075, 91-98.	2.3	21
111	Detection of Sotatercept (ACEâ€011) in human serum by SARâ€₱AGE and western single blotting. Drug Testing and Analysis, 2018, 10, 927-937.	2.6	9
112	Annual bannedâ€substance review: Analytical approaches in human sports drug testing. Drug Testing and Analysis, 2018, 10, 9-27.	2.6	19
113	Combined detection of the ActRIIâ€Fc fusion proteins Sotatercept (ActRIIAâ€Fc) and Luspatercept (modified) Tj Testing and Analysis, 2018, 10, 1714-1721.	ETQq1 1 (2.6).784314 rg <mark>B</mark> 14
114	Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatography–high resolution mass spectrometry. Drug Testing and Analysis, 2018, 10, 1761-1768.	2.6	31
115	Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (<) Tj ETQq1 1 0.7 2018, 10, 1755-1760.	784314 rg 2.6	BT /Overlock 22
116	Effects of 3 Weeks of Oral Low-Dose Cobalt on Hemoglobin Mass and Aerobic Performance. Frontiers in Physiology, 2018, 9, 1289.	2.8	10
117	Studies on thein vivometabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. Drug Testing and Analysis, 2018, 10, 1646-1656.	2.6	17
118	Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway. Nitric Oxide - Biology and Chemistry, 2018, 81, 28-35.	2.7	36
119	Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. International Journal of Legal Medicine, 2018, 132, 1645-1657.	2.2	10
120	Case Study: Atypical <i>δ</i> ¹³ C values of urinary norandrosterone. Drug Testing and Analysis, 2018, 10, 1728-1733.	2.6	9
121	Updated protocols for the detection of Sotatercept and Luspatercept in human serum. Drug Testing and Analysis, 2018, 10, 1708-1713.	2.6	9
122	Analysis of new growth promoting black market products. Growth Hormone and IGF Research, 2018, 41, 1-6.	1.1	11
123	Development and validation of a multidimensional gas chromatography/combustion/isotope ratio mass spectrometry-based test method for analyzing urinary steroids in doping controls. Analytica Chimica Acta, 2018, 1030, 105-114.	5.4	17
124	Xenon elimination kinetics following brief exposure. Drug Testing and Analysis, 2017, 9, 666-670.	2.6	9
125	Human sports drug testing by mass spectrometry. Mass Spectrometry Reviews, 2017, 36, 16-46.	5.4	31
126	GHB-O-β-glucuronide in blood and urine is not a suitable tool for the extension of the detection window after GHB intake. Forensic Toxicology, 2017, 35, 263-274.	2.4	18

#	Article	IF	CITATIONS
127	Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. Substance Use and Misuse, 2017, 52, 742-753.	1.4	27
128	Simultaneous determination of insulin, DesB30 insulin, proinsulin, and C-peptide in human plasma samples by liquid chromatography coupled to high resolution mass spectrometry. Forensic Toxicology, 2017, 35, 106-113.	2.4	20
129	Analysis of taxine B/isotaxine B in a plasma specimen by LC–MS/MS in a case of fatal poisoning: concealed suicide by ingestion of yew (Taxus L.) leaves of a patient with a long-term history of borderline personality disorder. Forensic Toxicology, 2017, 35, 421-427.	2.4	6
130	The atypical excretion profile of meldonium: Comparison of urinary detection windows after single- and multiple-dose application in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 175-179.	2.8	12
131	Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YKâ€11 for doping control purposes. Rapid Communications in Mass Spectrometry, 2017, 31, 1175-1183.	1.5	19
132	Expanding analytical options in sports drug testing: Mass spectrometric detection of prohibited substances in exhaled breath. Rapid Communications in Mass Spectrometry, 2017, 31, 1290-1296.	1.5	29
133	Implementation of the prolyl hydroxylase inhibitor Roxadustat (FGâ€4592) and its main metabolites into routine doping controls. Drug Testing and Analysis, 2017, 9, 1768-1778.	2.6	25
134	Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots. Clinical Mass Spectrometry, 2017, 6, 13-20.	1.9	7
135	Characterization of <i>in vitro</i> generated metabolites of selected peptides <2ÂkDa prohibited in sports. Drug Testing and Analysis, 2017, 9, 1799-1803.	2.6	15
136	Epiandrosterone sulfate prolongs the detectability of testosterone, 4â€androstenedione, and dihydrotestosterone misuse by means of carbon isotope ratio mass spectrometry. Drug Testing and Analysis, 2017, 9, 1695-1703.	2.6	41
137	Carbon isotope ratios of endogenous steroids in Belgian Blue and Holstein cattle: Method development, reference population studies and application to steroid misuse control. Rapid Communications in Mass Spectrometry, 2017, 31, 1793-1802.	1.5	2
138	Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1064, 124-138.	2.3	36
139	Antibodyâ€based strategies for the detection of Luspatercept (ACEâ€536) in human serum. Drug Testing and Analysis, 2017, 9, 1721-1730.	2.6	16
140	Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications. Expert Review of Proteomics, 2017, 14, 799-807.	3.0	20
141	Probing for corticotropin-releasing hormone (CRH) in human blood for doping control purposes using immunoaffinity purification and LC-HRMS/MS. Analytical Methods, 2017, 9, 4304-4310.	2.7	6
142	Determination of LongR 3 -IGF-I, R 3 -IGF-I, Des1-3 IGF-I and their metabolites in human plasma samples by means of LC-MS. Growth Hormone and IGF Research, 2017, 35, 33-39.	1.1	12
143	Development and validation of a HPLC–QTOF-MS method for the determination of GHB-β-O-glucuronide and GHB-4-sulfate in plasma and urine. Forensic Toxicology, 2017, 35, 77-85.	2.4	9
144	Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. Drug Testing and Analysis, 2017, 9, 1372-1384.	2.6	9

#	Article	IF	CITATIONS
145	Mass spectrometric characterization of the hypoxiaâ€inducible factor (HIF) stabilizer drug candidate BAY 85â€3934 (molidustat) and its glucuronidated metabolite BAYâ€348, and their implementation into routine doping controls. Drug Testing and Analysis, 2017, 9, 61-67.	2.6	16
146	Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2017, 134, 228-236.	2.8	20
147	Annual bannedâ€substance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2017, 9, 6-29.	2.6	16
148	Applications of Isotope Ratio Mass Spectrometry in Sports Drug Testing Accounting for Isotope Fractionation in Analysis of Biological Samples. Methods in Enzymology, 2017, 596, 403-432.	1.0	18
149	Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. Drug Testing and Analysis, 2016, 8, 858-863.	2.6	14
150	Analytical detection of trimetazidine produced by metabolic conversion of lomerizine in doping control analysis. Drug Testing and Analysis, 2016, 8, 869-874.	2.6	10
151	Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. Journal of Separation Science, 2016, 39, 333-341.	2.5	40
152	Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using highâ€resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 2016, 30, 833-842.	1.5	20
153	Nickel in equine sports drug testing – pilot study results on urinary nickel concentrations. Rapid Communications in Mass Spectrometry, 2016, 30, 982-984.	1.5	8
154	The 34 th Manfred Donike Workshop on Doping Analysis. Drug Testing and Analysis, 2016, 8, 1108-1108.	2.6	0
155	Sports drug testing using complementary matrices: Advantages and limitations. Journal of Pharmaceutical and Biomedical Analysis, 2016, 130, 220-230.	2.8	97
156	Analyses of Meldonium (Mildronate) from Blood, Dried Blood Spots (DBS), and Urine Suggest Drug Incorporation into Erythrocytes. International Journal of Sports Medicine, 2016, 37, 500-502.	1.7	27
157	Identification of Selected <i>in vitro</i> -Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes. European Journal of Mass Spectrometry, 2016, 22, 49-59.	1.0	12
158	Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 482-496.	2.8	48
159	Testing for the erythropoiesisâ€stimulating agent Sotatercept/ACEâ€011 (ActRIIAâ€Fc) in serum by means of Western blotting and LCâ€HRMS. Drug Testing and Analysis, 2016, 8, 1152-1161.	2.6	24
160	Annual bannedâ€substance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2016, 8, 7-29.	2.6	36
161	Evaluation of AMGEN clone 9G8A antiâ€Epo antibody for application in doping control. Drug Testing and Analysis, 2016, 8, 1131-1137.	2.6	3
162	Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. Forensic Science International, 2016, 267, 166-172.	2.2	27

#	Article	IF	CITATIONS
163	Genotypeâ€dependent metabolism of exogenous testosterone – new biomarkers result in prolonged detectability. Drug Testing and Analysis, 2016, 8, 1163-1173.	2.6	33
164	Analytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 2016, 408, 6431-6442.	3.7	2
165	Optimization of an online heartâ€cutting multidimensional gas chromatography cleanâ€up step for isotopic ratio mass spectrometry and simultaneous quadrupole mass spectrometry measurements of endogenous anabolic steroid in urine. Drug Testing and Analysis, 2016, 8, 1204-1211.	2.6	22
166	Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs. Rapid Communications in Mass Spectrometry, 2016, 30, 635-651.	1.5	35
167	Mitragynine (Kratom) ―monitoring in sports drug testing. Drug Testing and Analysis, 2016, 8, 1114-1118.	2.6	10
168	In vitro elucidation of the metabolic profile of the synthetic cannabinoid receptor agonists JWH-175 and JWH-176. Forensic Toxicology, 2016, 34, 353-362.	2.4	6
169	Myostatin inhibitors in sports drug testing: Detection of myostatinâ€neutralizing antibodies in plasma/serum by affinity purification and Western blotting. Proteomics - Clinical Applications, 2016, 10, 195-205.	1.6	10
170	Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 68-76.	2.8	13
171	Solutions Advertised as Erythropoiesis-stimulating Products were Found to Contain Undeclared Cobalt and Nickel Species. International Journal of Sports Medicine, 2016, 37, 82-84.	1.7	13
172	Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2016, 123, 132-140.	2.8	39
173	Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry, 2016, 408, 3145-3153.	3.7	30
174	Revisiting the metabolism of 19-nortestosterone using isotope ratio and high resolution/high accuracy mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2016, 162, 80-91.	2.5	20
175	Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2016, 44, 227-237.	3.3	23
176	Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis. Scandinavian Journal of Rheumatology, 2016, 45, 347-355.	1.1	15
177	Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PLoS ONE, 2016, 11, e0150453.	2.5	6
178	Factitious administration of analogue insulin to a 2-year-old child. British Journal of Diabetes, 2016, 16, 82.	0.2	6
179	<i>In vitro</i> Metabolism Studies on the Selective Androgen Receptor Modulator LG121071 and its Implementation into Human Doping Controls Using Liquid Chromatography-Mass Spectrometry. European Journal of Mass Spectrometry, 2015, 21, 27-36.	1.0	19
180	Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRPâ€1, GHRPâ€2, GHRPâ€6, Hexarelin, and Ipamorelin. Drug Testing and Analysis, 2015, 7, 919-925.	2.6	35

#	Article	IF	CITATIONS
181	Complementing the characterization of <i>in vivo</i> generated <i>N</i> â€glucuronic acid conjugates of stanozolol by collision cross section computation and analysis. Drug Testing and Analysis, 2015, 7, 1050-1056.	2.6	17
182	Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls. Drug Testing and Analysis, 2015, 7, 1057-1062.	2.6	9
183	Detection of testosterone esters in blood. Drug Testing and Analysis, 2015, 7, 983-989.	2.6	36
184	Characterization of a nonâ€approved selective androgen receptor modulator drug candidate sold via the Internet and identification of <i>in vitro</i> generated phaseâ€I metabolites for human sports drug testing. Rapid Communications in Mass Spectrometry, 2015, 29, 991-999.	1.5	33
185	Expanded test method for peptides >2 kDa employing immunoaffinity purification and LCâ€HRMS/MS. Drug Testing and Analysis, 2015, 7, 990-998.	2.6	33
186	Annual bannedâ€ s ubstance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2015, 7, 1-20.	2.6	30
187	Characterization of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposes. Drug Testing and Analysis, 2015, 7, 673-683.	2.6	32
188	Studies on the collisionâ€induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing. Journal of Mass Spectrometry, 2015, 50, 407-417.	1.6	5
189	Formation of the diuretic chlorazanil from the antimalarial drug proguanil—Implications for sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 208-213.	2.8	10
190	Effects of Exercise on the Urinary Proteome. Advances in Experimental Medicine and Biology, 2015, 845, 121-131.	1.6	17
191	EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS. Journal of the American Society for Mass Spectrometry, 2015, 26, 1617-1625.	2.8	6
192	Determination of Synacthen® in dried blood spots for doping control analysis using liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2015, 407, 4709-4720.	3.7	24
193	"Dilute-and-inject―multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing. Analytical and Bioanalytical Chemistry, 2015, 407, 5365-5379.	3.7	48
194	Mildronate (Meldonium) in professional sports – monitoring doping control urine samples using hydrophilic interaction liquid chromatography – high resolution/high accuracy mass spectrometry. Drug Testing and Analysis, 2015, 7, 973-979.	2.6	48
195	Metabolism of human insulin after subcutaneous administration: A possible means to uncover insulin misuse. Analytica Chimica Acta, 2015, 897, 53-61.	5.4	23
196	Dried blood spots (DBS) in doping controls: a complementary matrix for improved in- and out-of-competition sports drug testing strategies. Analytical Methods, 2015, 7, 7596-7605.	2.7	23
197	Seizures of doping substances at the Swiss Border — a descriptive investigation. Forensic Science International, 2015, 257, 359-368.	2.2	18
198	Urine analysis concerning xenon for doping control purposes. Rapid Communications in Mass Spectrometry, 2015, 29, 61-66.	1.5	15

#	Article	IF	CITATIONS
199	Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015. British Journal of Sports Medicine, 2014, 48, 801-806.	6.7	20
200	Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics, 2014, 11, 663-673.	3.0	26
201	Screening and confirmation of myoâ€inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Drug Testing and Analysis, 2014, 6, 1102-1107.	2.6	12
202	Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LCâ€IMâ€MS). Drug Testing and Analysis, 2014, 6, 1125-1132.	2.6	62
203	Isolation, Enrichment, and Analysis of Erythropoietins in Anti-Doping Analysis by Receptor-Coated Magnetic Beads and Liquid Chromatography–Mass Spectrometry. Analytical Chemistry, 2014, 86, 12014-12021.	6.5	17
204	Detection of an unknown fusion protein in confiscated black market products. Drug Testing and Analysis, 2014, 6, 1117-1124.	2.6	13
205	Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Growth Hormone and IGF Research, 2014, 24, 276-280.	1.1	15
206	Annual bannedâ€ s ubstance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2014, 6, 164-184.	2.6	20
207	Determination of ¹³ C/ ¹² C ratios of endogenous urinary 5â€aminoâ€imidazoleâ€4 arboxamide 1βâ€Dâ€ribofuranoside (AICAR). Rapid Communications in Mass Spect 2014, 28, 1194-1202.	ronsetry,	22
208	Use of dried blood spots in doping control analysis of anabolic steroid esters. Journal of Pharmaceutical and Biomedical Analysis, 2014, 96, 21-30.	2.8	51
209	Anabolic agents: recent strategies for their detection and protection from inadvertent doping. British Journal of Sports Medicine, 2014, 48, 820-826.	6.7	92
210	Measuring xenon in human plasma and blood by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 1501-1506.	1.5	25
211	Isotopeâ€dilution mass spectrometric quantification of the prodrug lisdexamfetamine in human urine in doping control analysis. Rapid Communications in Mass Spectrometry, 2014, 28, 781-786.	1.5	6
212	Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 649-659.	2.8	20
213	Quantifying cobalt in doping control urine samples – a pilot study. Drug Testing and Analysis, 2014, 6, 1186-1190.	2.6	26
214	Carbon Isotope Ratio Analysis of Steroids by High-Temperature Liquid Chromatography-Isotope Ratio Mass Spectrometry. Analytical Chemistry, 2014, 86, 2297-2302.	6.5	14
215	Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches. Drug Testing and Analysis, 2014, 6, 1197-1205.	2.6	16
216	Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry. Clinical Chemistry, 2014, 60, 541-548.	3.2	96

#	Article	IF	CITATIONS
217	Identification of black market products and potential doping agents in Germany 2010–2013. European Journal of Clinical Pharmacology, 2014, 70, 1303-1311.	1.9	84
218	Isolation and characterization of a β-glucuronide of hydroxylated SARM S1 produced using a combination of biotransformation and chemical oxidation. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 36-39.	2.8	5
219	Quantification of intact human insulinâ€like growth factorâ€l in serum by nanoâ€ultrahighâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 1426-1432.	1.5	30
220	Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Journal of Pharmaceutical and Biomedical Analysis, 2014, 101, 66-83.	2.8	53
221	Clycerol administration before endurance exercise: metabolism, urinary glycerol excretion and effects on dopingâ€relevant blood parameters. Drug Testing and Analysis, 2014, 6, 202-209.	2.6	13
222	Liquid Chromatography-High Resolution/High Accuracy (Tandem) Mass Spectrometry-Based Identification of <i>in vivo</i> Generated Metabolites of the Selective Androgen Receptor Modulator ACP-105 for Doping Control Purposes. European Journal of Mass Spectrometry, 2014, 20, 73-83.	1.0	16
223	Synthesis of Four SIRT1 Activators Based on an Imidazo[1,2-b]thiazole Structure, in vitro Derived Metabolites and Deuterated Analogs. Open Organic Chemistry Journal, 2014, 8, 19-23.	0.9	1
224	Traditional Chinese medicine and sports drug testing: identification of natural steroid administration in doping control urine samples resulting from musk (pod) extracts. British Journal of Sports Medicine, 2013, 47, 109-114.	6.7	37
225	Synthesis, characterization, and detection of new oxandrolone metabolites as long-term markers in sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 8285-8294.	3.7	52
226	Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. Analytical and Bioanalytical Chemistry, 2013, 405, 9703-9709.	3.7	19
227	Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing. Drug Testing and Analysis, 2013, 5, 810-818.	2.6	62
228	Hydrogen isotope ratio mass spectrometry and highâ€resolution/highâ€accuracy mass spectrometry in metabolite identification studies: Detecting target compounds for sports drug testing. Rapid Communications in Mass Spectrometry, 2013, 27, 1904-1912.	1.5	25
229	Targeting prohibited substances in doping control blood samples by means of chromatographic–mass spectrometric methods. Analytical and Bioanalytical Chemistry, 2013, 405, 9655-9667.	3.7	20
230	Mass spectrometric characterization of glucuronides formed by a new concept, combining Cunninghamella elegans with TEMPO. Journal of Pharmaceutical and Biomedical Analysis, 2013, 84, 278-284.	2.8	8
231	Selective androgen receptor modulators:in vitroandin vivometabolism and analysis. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2013, 30, 1517-1526.	2.3	24
232	Detection of small interfering RNA (siRNA) by mass spectrometry procedures in doping controls. Drug Testing and Analysis, 2013, 5, 853-860.	2.6	17
233	Fragmentation studies of SIRT1â€activating drugs and their detection in human plasma for doping control purposes. Rapid Communications in Mass Spectrometry, 2013, 27, 35-50.	1.5	12
234	Mass spectrometric studies on the <i>in vitro</i> generated metabolites of SIRT1 activating drugs for doping control purposes. Journal of Mass Spectrometry, 2013, 48, 830-843.	1.6	8

#	Article	IF	CITATIONS
235	In vitro synthesis and characterisation of three fenoterol sulfoconjugates detected in fenoterol post-administration urine samples. Analytical and Bioanalytical Chemistry, 2013, 405, 9477-9487.	3.7	4
236	Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 5455-5466.	3.7	36
237	Monitoring phosphodiesteraseâ€4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing. Rapid Communications in Mass Spectrometry, 2013, 27, 993-1004.	1.5	8
238	Annual bannedâ€ s ubstance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2013, 5, 1-19.	2.6	30
239	Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?. Rapid Communications in Mass Spectrometry, 2013, 27, 507-512.	1.5	46
240	Effect of changes in the deuterium content of drinking water on the hydrogen isotope ratio of urinary steroids in the context of sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 2911-2921.	3.7	2
241	Monitoring drug residues in donor blood/plasma samples using LCâ€(MS)/MS – a pilot study. Drug Testing and Analysis, 2013, 5, 380-383.	2.6	11
242	Post-mortem vitreous humour as potential specimen for detection of insulin analogues by LC–MS/MS. Forensic Science International, 2013, 233, 328-332.	2.2	26
243	Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin. Bioanalysis, 2013, 5, 587-602.	1.5	17
244	Synthesis, Mass Spectrometric Characterization, and Analysis of the PPARδ Agonist GW1516 and Its Major Human Metabolites: Targets in Sports Drug Testing. Methods in Molecular Biology, 2013, 952, 301-312.	0.9	10
245	Adverse analytical findings with clenbuterol among Uâ€17 soccer players attributed to food contamination issues. Drug Testing and Analysis, 2013, 5, 372-376.	2.6	47
246	Ultrahigh pressure liquid chromatography–(tandem) mass spectrometry in human sports drug testing: Possibilities and limitations. Journal of Chromatography A, 2013, 1292, 38-50.	3.7	41
247	Using electrochemistry for metabolite simulation and synthesis in preventive doping research: application to the Rycal S107 and the PPARÎ′-agonist GW1516. Analytical Methods, 2013, 5, 1214.	2.7	1
248	Expanding sports drug testing assays: Mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACPâ€105. Rapid Communications in Mass Spectrometry, 2013, 27, 1173-1182.	1.5	20
249	AODâ€9604 does not influence the WADA hGH isoform immunoassay. Drug Testing and Analysis, 2013, 5, 850-852.	2.6	8
250	The fungus <i>Cunninghamella elegans</i> can produce human and equine metabolites of selective androgen receptor modulators (SARMs). Xenobiotica, 2013, 43, 409-420.	1.1	17
251	Metaâ€analysis: Effects of glycerol administration on plasma volume, haemoglobin, and haematocrit. Drug Testing and Analysis, 2013, 5, 896-899.	2.6	13
252	Effects of gamma irradiation and 15 days of subsequent ex vivo storage on the cytosolic red blood cell proteome analyzed by 2Dâ€ÐIGE and Orbitrap MS. Proteomics - Clinical Applications, 2013, 7, 561-570.	1.6	5

#	Article	IF	CITATIONS
253	RBC-NOS-Dependent S-Nitrosylation of Cytoskeletal Proteins Improves RBC Deformability. PLoS ONE, 2013, 8, e56759.	2.5	135
254	Detection of illegal use of androgens and selective androgen receptor modulators. , 2012, , 517-534.		7
255	Analytical challenges in the detection of peptide hormones for anti-doping purposes. Bioanalysis, 2012, 4, 1577-1590.	1.5	29
256	Detection of Peginesatide in Equine Serum Using Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. European Journal of Mass Spectrometry, 2012, 18, 407-412.	1.0	6
257	New potential markers for the detection of boldenone misuse. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 239-246.	2.5	59
258	Mass spectrometric detection of peginesatide in human urine in doping control analysis. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 512-517.	2.8	14
259	Investigations on hydrogen isotope ratios of endogenous urinary steroids: referenceâ€populationâ€based thresholds and proofâ€ofâ€concept. Drug Testing and Analysis, 2012, 4, 717-727.	2.6	32
260	Influence of repeated subcutaneous Gâ€CSF injections on selected blood parameters relevant for monitoring programmes in sports drug testing. Drug Testing and Analysis, 2012, 4, 798-802.	2.6	3
261	Storageâ€induced changes of the cytosolic red blood cell proteome analyzed by 2D DIGE and highâ€resolution/highâ€accuracy MS. Proteomics, 2012, 12, 3263-3272.	2.2	17
262	Immunoaffinity purification of peptide hormones prior to liquid chromatography–mass spectrometry in doping controls. Methods, 2012, 56, 230-235.	3.8	85
263	Investigations of the microbial transformation of cortisol to prednisolone in urine samples. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 54-60.	2.5	34
264	Metabolism of Growth Hormone Releasing Peptides. Analytical Chemistry, 2012, 84, 10252-10259.	6.5	47
265	Validated hemoglobinâ€depletion approach for red blood cell lysate proteome analysis by means of 2 <scp>D PAGE</scp> and <scp>O</scp> rbitrap <scp>MS</scp> . Electrophoresis, 2012, 33, 2537-2545.	2.4	19
266	Characterization of InÂVitro Synthesized Equine Metabolites of the Selective Androgen Receptor Modulators S24 and S4. Journal of Equine Veterinary Science, 2012, 32, 562-568.	0.9	13
267	Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. Journal of Chromatography A, 2012, 1259, 251-257.	3.7	54
268	Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 1813-1822.	3.7	65
269	Clenbuterol – regional food contamination a possible source for inadvertent doping in sports. Drug Testing and Analysis, 2012, 4, 534-538.	2.6	62
270	Detection of EPOâ€Fc fusion protein in human blood: Screening and confirmation protocols for sports drug testing. Drug Testing and Analysis, 2012, 4, 818-829.	2.6	24

#	Article	IF	CITATIONS
271	Identification and characterization of urinary prenylamine metabolites by means of liquid chromatographyâ€tandem mass spectrometry. Drug Testing and Analysis, 2012, 4, 701-716.	2.6	6
272	Recent instrumental progress in mass spectrometry: advancing resolution, accuracy, and speed of drug detection. Drug Testing and Analysis, 2012, 4, 242-245.	2.6	26
273	Hypoxiaâ€inducible factor stabilizers and other smallâ€molecule erythropoiesisâ€stimulating agents in current and preventive doping analysis. Drug Testing and Analysis, 2012, 4, 830-845.	2.6	74
274	Analysis of octopamine in human doping control samples. Biomedical Chromatography, 2012, 26, 610-615.	1.7	11
275	Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. Analytical and Bioanalytical Chemistry, 2012, 403, 2715-2724.	3.7	58
276	Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Analytical and Bioanalytical Chemistry, 2012, 403, 1279-1289.	3.7	136
277	Plasticizers excreted in urine: indication of autologous blood transfusion in sports. Transfusion, 2012, 52, 647-657.	1.6	35
278	Sports drug testing: Analytical aspects of selected cases of suspected, purported, and proven urine manipulation. Journal of Pharmaceutical and Biomedical Analysis, 2012, 57, 26-32.	2.8	33
279	Measuring insulin in human vitreous humour using LCâ€MS/MS. Drug Testing and Analysis, 2012, 4, 53-56.	2.6	42
280	<i>Drug Testing and Analysis'</i> oneâ€year impact factor. Drug Testing and Analysis, 2012, 4, 1-1.	2.6	1
281	Annual bannedâ€substance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2012, 4, 2-16.	2.6	14
282	Structure Elucidation of the Diagnostic Product Ion at m/z 97 Derived from Androst-4-en-3-One-Based Steroids by ESI-CID and IRMPD Spectroscopy. Journal of the American Society for Mass Spectrometry, 2012, 23, 537-546.	2.8	23
283	Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst, The, 2011, 136, 1003-1012.	3.5	57
284	Determination of Vasopressin and Desmopressin in urine by means of liquid chromatography coupled to quadrupole time-of-flight mass spectrometry for doping control purposes. Analytica Chimica Acta, 2011, 707, 107-113.	5.4	47
285	Evaluation of commercially available assays for the measurement of equine insulin. Domestic Animal Endocrinology, 2011, 41, 81-90.	1.6	58
286	Doping control analysis of selected peptide hormones using LC–MS(/MS). Forensic Science International, 2011, 213, 35-41.	2.2	39
287	Screening for the synthetic cannabinoid JWHâ€018 and its major metabolites in human doping controls. Drug Testing and Analysis, 2011, 3, 609-620.	2.6	113
288	Annual bannedâ€substance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2011, 3, 1-14.	2.6	44

#	Article	IF	CITATIONS
289	Trafficking of drug candidates relevant for sports drug testing: Detection of nonâ€approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Testing and Analysis, 2011, 3, 331-336.	2.6	45
290	RNA interference for performance enhancement and detection in doping control. Drug Testing and Analysis, 2011, 3, 661-667.	2.6	9
291	Dried blood spots (DBS) for doping control analysis. Drug Testing and Analysis, 2011, 3, 806-813.	2.6	42
292	Zeranol: doping offence or mycotoxin? A caseâ€related study. Drug Testing and Analysis, 2011, 3, 777-783.	2.6	22
293	Urinary excretion of exogenous glycerol administration at rest. Drug Testing and Analysis, 2011, 3, 877-882.	2.6	13
294	Identification of fibroblast growth factor 1 (FGFâ€1) in a black market product. Drug Testing and Analysis, 2011, 3, 791-797.	2.6	16
295	Development of liquid chromatographyâ€ŧandem mass spectrometryâ€based analytical assays for the determination of HIF stabilizers in preventive doping research. Drug Testing and Analysis, 2011, 3, 756-770.	2.6	27
296	Highâ€throughput screening for various classes of doping agents using a new â€~diluteâ€andâ€shoot' liquid chromatographyâ€tandem mass spectrometry multiâ€target approach. Drug Testing and Analysis, 2011, 3, 836-850.	2.6	67
297	Di(2â€ethylhexyl) phthalate metabolites as markers for blood transfusion in doping control: Intraâ€individual variability of urinary concentrations. Drug Testing and Analysis, 2011, 3, 892-895.	2.6	13
298	Screening for benfluorex and its major urinary metabolites in routine doping controls. Analytical and Bioanalytical Chemistry, 2011, 401, 543-551.	3.7	11
299	Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. Analytical and Bioanalytical Chemistry, 2011, 401, 517-528.	3.7	36
300	Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 401, 507-516.	3.7	83
301	Current role of LC-MS(/MS) in doping control. Analytical and Bioanalytical Chemistry, 2011, 401, 405-420.	3.7	86
302	Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Analytical and Bioanalytical Chemistry, 2011, 401, 493-505.	3.7	66
303	Anti-doping analysis. Analytical and Bioanalytical Chemistry, 2011, 401, 387-388.	3.7	4
304	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator Sâ€22 to identify potential targets for routine doping controls. Rapid Communications in Mass Spectrometry, 2011, 25, 2187-2195.	1.5	38
305	Synthesis, characterisation, and mass spectrometric detection of a pegylated EPOâ€mimetic peptide for sports drug testing purposes. Rapid Communications in Mass Spectrometry, 2011, 25, 2115-2123.	1.5	33
306	Investigation of the <i>in vitro</i> metabolism of the emerging drug candidate S107 for dopingâ€preventive purposes. Journal of Mass Spectrometry, 2011, 46, 112-130.	1.6	33

#	Article	IF	CITATIONS
307	Wiley-Interscience Series in Mass Spectrometry. , 2010, , 361-361.		1
308	Mass Spectrometry-Based Characterization of New Drugs and Methods of Performance Manipulation in Doping Control Analysis. European Journal of Mass Spectrometry, 2010, 16, 301-312.	1.0	12
309	Identification of the growthâ€hormoneâ€releasing peptideâ€2 (GHRPâ€2) in a nutritional supplement. Drug Testing and Analysis, 2010, 2, 144-148.	2.6	52
310	Annual bannedâ€substance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2010, 2, 149-161.	2.6	15
311	Confiscated black market products and nutritional supplements with nonâ€approved ingredients analyzed in the cologne doping control laboratory 2009. Drug Testing and Analysis, 2010, 2, 533-537.	2.6	92
312	Characterization of <i>in vitro</i> generated metabolites of the selective androgen receptor modulators Sâ€22 and Sâ€23 and <i>in vivo</i> comparison to postâ€administration canine urine specimens. Drug Testing and Analysis, 2010, 2, 589-598.	2.6	41
313	Reporting and managing elevated testosterone/epitestosterone ratios-Novel aspects after five years' experience. Drug Testing and Analysis, 2010, 2, 637-642.	2.6	26
314	Characterization of two major urinary metabolites of the PPARÎ ² -agonist GW1516 and implementation of the drug in routine doping controls. Analytical and Bioanalytical Chemistry, 2010, 396, 2479-2491.	3.7	43
315	Quantification of urinary AICAR concentrations as a matter of doping controls. Analytical and Bioanalytical Chemistry, 2010, 396, 2899-2908.	3.7	34
316	Anabolic, doping, and lifestyle drugs, and selected metabolites in wastewater—detection, quantification, and behaviour monitored by high-resolution MS and MS n before and after sewage treatment. Analytical and Bioanalytical Chemistry, 2010, 398, 1207-1229.	3.7	61
317	Mass spectrometric detection of siRNA in plasma samples for doping control purposes. Analytical and Bioanalytical Chemistry, 2010, 398, 1305-1312.	3.7	22
318	In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Analytical and Bioanalytical Chemistry, 2010, 398, 2141-2153.	3.7	131
319	Analysis of selective androgen receptor modulators by gas chromatography-microchip atmospheric pressure photoionization-mass spectrometry. Journal of the American Society for Mass Spectrometry, 2010, 21, 310-316.	2.8	21
320	Effects of endurance exercise on the urinary proteome analyzed by 2â€Ð PAGE and Orbitrap MS. Proteomics - Clinical Applications, 2010, 4, 568-576.	1.6	24
321	Comprehensive plasmaâ€screening for known and unknown substances in doping controls. Rapid Communications in Mass Spectrometry, 2010, 24, 1124-1132.	1.5	60
322	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (Sâ€4) for routine doping control purposes. Rapid Communications in Mass Spectrometry, 2010, 24, 2245-2254.	1.5	48
323	Determination of ¹³ C/ ¹² C ratios of endogenous urinary steroids excreted as sulpho conjugates. Rapid Communications in Mass Spectrometry, 2010, 24, 3171-3181.	1.5	46
324	Detection of Surreptitious Administration of Analog Insulin to an 8-Week-Old Infant. Pediatrics, 2010, 125, e1236-e1240.	2.1	39

#	Article	IF	CITATIONS
325	Stimulants and Doping in Sport. Endocrinology and Metabolism Clinics of North America, 2010, 39, 89-105.	3.2	28
326	SERMs and SARMs: Detection of their activities with yeast based bioassays. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 85-92.	2.5	32
327	Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Hormone and IGF Research, 2010, 20, 386-390.	1.1	33
328	Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. Journal of Mass Spectrometry, 2009, 44, 442-460.	1.6	56
329	Doping control analysis of emerging drugs in human plasma – identification of GW501516, Sâ€107, JTVâ€519, and Sâ€40503. Rapid Communications in Mass Spectrometry, 2009, 23, 1139-1146.	1.5	34
330	Determination of the deuterium/hydrogen ratio of endogenous urinary steroids for doping control purposes. Rapid Communications in Mass Spectrometry, 2009, 23, 1917-1926.	1.5	31
331	Electron ionization mass spectrometry of the ryanodine receptor-based Ca2+ -channel stabilizer S-107 and its implementation into routine doping control. Rapid Communications in Mass Spectrometry, 2009, 23, 2363-2370.	1.5	10
332	Determination of Synacthen in urine for sports drug testing by means of nanoâ€ultraâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 2669-2674.	1.5	38
333	Detection and pharmacokinetics of tetrahydrogestrinone in horses. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 197-202.	1.3	10
334	Unusual mass spectrometric dissociation pathway of protonated isoquinoline-3-carboxamides due to multiple reversible water adduct formation in the gas phase. Journal of the American Society for Mass Spectrometry, 2009, 20, 2034-2048.	2.8	43
335	Insulin. Handbook of Experimental Pharmacology, 2009, , 209-226.	1.8	45
336	Temporal indication of cannabis use by means of THC glucuronide determination. Drug Testing and Analysis, 2009, 1, 505-510.	2.6	26
337	Screening for the calstabinâ€ryanodine receptor complex stabilizers JTVâ€519 and Sâ€107 in doping control analysis. Drug Testing and Analysis, 2009, 1, 32-42.	2.6	15
338	Proteolysis and autolysis of proteases and the detection of degradation products in doping control. Drug Testing and Analysis, 2009, 1, 81-86.	2.6	24
339	Detection of the protease Bacillolysin in dopingâ€control urine samples. Drug Testing and Analysis, 2009, 1, 143-145.	2.6	12
340	Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nanoâ€UPLC coupled with highâ€resolution/highâ€accuracy mass spectrometry. Drug Testing and Analysis, 2009, 1, 219-227.	2.6	72
341	Application of FAIMS to anabolic androgenic steroids in sport drug testing. Drug Testing and Analysis, 2009, 1, 545-553.	2.6	44
342	Comparison of the urinary protein patterns of athletes by 2Dâ€gel electrophoresis and mass spectrometry—a pilot study. Drug Testing and Analysis, 2009, 1, 382-386.	2.6	21

#	Article	IF	CITATIONS
343	Terbutaline sulfoconjugate: characterization and urinary excretion monitored by LC/ESIâ€MS/MS. Drug Testing and Analysis, 2009, 1, 568-575.	2.6	18
344	Annual bannedâ€substance review: the Prohibited List 2008—analytical approaches in human sports drug testing. Drug Testing and Analysis, 2009, 1, 4-13.	2.6	13
345	Detection of the arylpropionamideâ€derived selective androgen receptor modulator (SARM) Sâ€4 (Andarine) in a blackâ€market product. Drug Testing and Analysis, 2009, 1, 387-392.	2.6	57
346	Identification of Human Pituitary Growth Hormone Variants by Mass Spectrometry. Journal of Proteome Research, 2009, 8, 1071-1076.	3.7	40
347	Doping control analysis of trenbolone and related compounds using liquid chromatography–tandem mass spectrometry. Steroids, 2009, 74, 315-321.	1.8	31
348	Doping Control Analysis of Metamfepramone and Two Major Metabolites Using Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2009, 15, 507-515.	1.0	8
349	Synthetic Anabolic Agents: Steroids and Nonsteroidal Selective Androgen Receptor Modulators. Handbook of Experimental Pharmacology, 2009, , 99-126.	1.8	24
350	Mass Spectrometry-Based Analysis of IGF-1 and hGH. Handbook of Experimental Pharmacology, 2009, , 201-207.	1.8	13
351	Induction of micronuclei in V79 cells by the anabolic doping steroids tetrahydrogestrinone and trenbolone. Archives of Toxicology, 2008, 82, 257-263.	4.2	23
352	Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC–MS/MS. Analytical and Bioanalytical Chemistry, 2008, 391, 251-261.	3.7	40
353	Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horseâ€racing. Rapid Communications in Mass Spectrometry, 2008, 22, 355-362.	1.5	36
354	Quantification of human insulinâ€like growth factorâ€1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 477-485.	1.5	103
355	Determination of ¹³ C/ ¹² C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. Rapid Communications in Mass Spectrometry, 2008, 22, 2161-2175.	1.5	151
356	Doping control analysis of tricyclic tetrahydroquinolineâ€derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 2471-2478.	1.5	36
357	Mass spectrometry of hydantoinâ€derived selective androgen receptor modulators. Journal of Mass Spectrometry, 2008, 43, 639-650.	1.6	32
358	Liquid chromatographic–mass spectrometric analysis of glucuronideâ€conjugated anabolic steroid metabolites: method validation and interlaboratory comparison. Journal of Mass Spectrometry, 2008, 43, 965-973.	1.6	55
359	Mass spectrometry of selective androgen receptor modulators. Journal of Mass Spectrometry, 2008, 43, 865-876.	1.6	66
360	Nutritional supplements cross ontaminated and faked with doping substances. Journal of Mass Spectrometry, 2008, 43, 892-902.	1.6	319

#	Article	IF	CITATIONS
361	Mass spectrometric determination of gonadotrophinâ€releasing hormone (GnRH) in human urine for doping control purposes by means of LC–ESIâ€MS/MS. Journal of Mass Spectrometry, 2008, 43, 908-915.	1.6	62
362	Factors influencing the steroid profile in doping control analysis. Journal of Mass Spectrometry, 2008, 43, 877-891.	1.6	227
363	Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrometry Reviews, 2008, 27, 35-50.	5.4	98
364	Detection of recombinant growth hormone in human plasma by a 2â€Ð PAGE method. Electrophoresis, 2008, 29, 4495-4502.	2.4	19
365	Rapid screening of polysaccharideâ€based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography–tandem mass spectrometry. Biomedical Chromatography, 2008, 22, 695-701.	1.7	25
366	Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation. Journal of the American Society for Mass Spectrometry, 2008, 19, 151-158.	2.8	30
367	New drugs and methods of doping and manipulation. Drug Discovery Today, 2008, 13, 59-66.	6.4	38
368	Leistungssteigernde Substanzen im LCâ€MS/MS. Nachrichten Aus Der Chemie, 2008, 56, 910-913.	0.0	0
369	Enzyme-assisted synthesis and structure characterization of glucuronide conjugates of eleven anabolic steroid metabolites. Steroids, 2008, 73, 257-265.	1.8	46
370	Aryl-Propionamide-Derived Selective Androgen Receptor Modulators: Liquid Chromatography-Tandem Mass Spectrometry Characterization of the in Vitro Synthesized Metabolites for Doping Control Purposes. Drug Metabolism and Disposition, 2008, 36, 571-581.	3.3	71
371	Analysis of Confiscated Black Market Drugs Using Chromatographic and Mass Spectrometric Approaches. Journal of Analytical Toxicology, 2008, 32, 232-240.	2.8	62
372	Use of an Electrochemically Synthesised Metabolite of a Selective Androgen Receptor Modulator for Mass Spectrometry-Based Sports Drug Testing. European Journal of Mass Spectrometry, 2008, 14, 163-170.	1.0	30
373	Illicit organogenesis. Organogenesis, 2008, 4, 264-271.	1.2	5
374	Determination of the prevalence of anabolic steroids, stimulants, and selected drugs subject to doping controls among elite sport students using analytical chemistry. Journal of Sports Sciences, 2008, 26, 1059-1065.	2.0	34
375	Discrimination of Recombinant and Endogenous Urinary Erythropoietin by Calculating Relative Mobility Values from SDS Gels. International Journal of Sports Medicine, 2008, 29, 1-6.	1.7	75
376	Quantitative Analysis of Urinary Glycerol Levels for Doping Control Purposes Using Gas Chromatography-Mass Spectrometry. European Journal of Mass Spectrometry, 2008, 14, 117-124.	1.0	30
377	Screening for Two Selective Androgen Receptor Modulators Using Gas Chromatography-Mass Spectrometry in Doping Control Analysis. European Journal of Mass Spectrometry, 2008, 14, 153-161.	1.0	29
378	Identification and Quantification of the Osmodiuretic Mannitol in Urine for Sports Drug Testing Using Cas Chromatography-Mass Spectrometry. European Journal of Mass Spectrometry, 2008, 14, 127-133.	1.0	17

#	Article	IF	CITATIONS
379	Doping Control Analysis of Methoxyphenamine Using Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2008, 14, 145-152.	1.0	11
380	Screening of In Vitro Synthesised Metabolites of 4,9,11-Trien-3-One Steroids by Liquid Chromatography-Mass Spectrometry. European Journal of Mass Spectrometry, 2008, 14, 181-189.	1.0	22
381	Determination of Selected Stimulants in Urine for Sports Drug Analysis by Solid Phase Extraction via Cation Exchange and Means of Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2008, 14, 135-143.	1.0	21
382	Emerging Drugs - Potential for Misuse in Sport and Doping Control Detection Strategies. Mini-Reviews in Medicinal Chemistry, 2007, 7, 533-539.	2.4	31
383	Proteases in Doping Control Analysis. International Journal of Sports Medicine, 2007, 28, 545-549.	1.7	39
384	Detection of Homologous Blood Transfusion. International Journal of Sports Medicine, 2007, 28, 633-637.	1.7	31
385	Detection of Dehydroepiandrosterone Misuse by Means of Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry. European Journal of Mass Spectrometry, 2007, 13, 419-426.	1.0	27
386	Determination of Tuaminoheptane in Doping Control Urine Samples. European Journal of Mass Spectrometry, 2007, 13, 213-221.	1.0	17
387	Doping-Control Analysis of the 5α-Reductase Inhibitor Finasteride: Determination of Its Influence on Urinary Steroid Profiles and Detection of Its Major Urinary Metabolite. Therapeutic Drug Monitoring, 2007, 29, 236-247.	2.0	44
388	Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites. Steroids, 2007, 72, 278-286.	1.8	34
389	Mass spectrometric identification of peptide hormones in doping-control analysis. Analyst, The, 2007, 132, 287-291.	3.5	33
390	Mass Spectrometric Identification of Degradation Products of Insulin and Its Long-Acting Analogues in Human Urine for Doping Control Purposes. Analytical Chemistry, 2007, 79, 2518-2524.	6.5	75
391	Mass spectrometry in sports drug testing: Structure characterization and analytical assays. Mass Spectrometry Reviews, 2007, 26, 79-107.	5.4	178
392	Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing. Rapid Communications in Mass Spectrometry, 2007, 21, 297-304.	1.5	41
393	Screening for 2â€quinolinoneâ€derived selective androgen receptor agonists in doping control analysis. Rapid Communications in Mass Spectrometry, 2007, 21, 3477-3486.	1.5	48
394	Longâ€ŧerm engraftment following transplantation of pig pancreatic primordia into nonâ€immunosuppressed diabetic rhesus macaques. Xenotransplantation, 2007, 14, 591-602.	2.8	49
395	Detection of manipulation in doping control urine sample collection: a multidisciplinary approach to determine identical urine samples. Analytical and Bioanalytical Chemistry, 2007, 388, 1539-1543.	3.7	38
396	Current role of LC–MS(/MS) in doping control. Analytical and Bioanalytical Chemistry, 2007, 388, 1351-1358.	3.7	75

#	Article	IF	CITATIONS
397	Doping Control Analysis of Intact Rapid-Acting Insulin Analogues in Human Urine by Liquid Chromatographyâ^'Tandem Mass Spectrometry. Analytical Chemistry, 2006, 78, 1897-1903.	6.5	91
398	Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry. Analyst, The, 2006, 131, 1021-1026.	3.5	53
399	Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. Toxicology Letters, 2006, 164, 16-23.	0.8	28
400	Determination of N-Desmethyl- and N-Bisdesmethyl Metabolites of Sibutramine in Doping Control Analysis Using Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2006, 12, 129-136.	1.0	30
401	Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Communications in Mass Spectrometry, 2006, 20, 870-876.	1.5	77
402	Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 1954-1962.	1.5	47
403	Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Communications in Mass Spectrometry, 2006, 20, 2252-2258.	1.5	114
404	Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes. Rapid Communications in Mass Spectrometry, 2006, 20, 3393-3402.	1.5	22
405	Determination of Synacthen in human plasma using immunoaffinity purification and liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 3551-3556.	1.5	38
406	Detection of Stanozolol and Its Major Metabolites in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry. Chromatographia, 2006, 64, 441-446.	1.3	33
407	Quantitative Determination of Adrenaline and Noradrenaline in Urine Using Liquid Chromatography-Tandem Mass Spectrometry. Chromatographia, 2006, 64, 587-591.	1.3	21
408	Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography–atmospheric pressure ionization-tandem mass spectrometry. Journal of Mass Spectrometry, 2006, 41, 332-338.	1.6	20
409	Impact of recent biochemical findings on the determination of free and bioavailable testosterone: evaluation and proposal for clinical use / Auswirkungen neuer biochemischer Befunde auf die Bestimmung von freiem und bioverfügbarem Testosteron: Evaluierung und Vorschlag für den klinischen Einsatz. Das Medizinische Laboratorium. 2006. 30. 492-505.	0.0	1
410	Analytik modifizierter Steroidhormone mittels Flüssigkeitschromatographie/Tandem-Massenspektrometrie Analysis of modified steroid hormones using liquid chromatography/tandem mass spectrometry. Das Medizinische Laboratorium, 2006, 30, 26-32.	0.0	2
411	Identification of Fentanyl, Alfentanil, Sufentanil, Remifentanil and Their Major Metabolites in Human Urine by Liquid Chromatography/Tandem Mass Spectrometry for Doping Control Purposes. European Journal of Mass Spectrometry, 2005, 11, 419-427.	1.0	49
412	Mass spectrometric analysis of androstan-17β-ol-3-one and androstadiene-17β-ol-3-one isomers. Journal of the American Society for Mass Spectrometry, 2005, 16, 1660-1669.	2.8	48
413	Quantification of Clenbuterol in Human Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. Chromatographia, 2005, 62, 435-439.	1.3	34
414	Examples of Doping Control Analysis by Liquid Chromatography-Tandem Mass Spectrometry: Ephedrines, Â-Receptor Blocking Agents, Diuretics, Sympathomimetics, and Cross-Linked Hemoglobins. Journal of Chromatographic Science, 2005, 43, 22-31.	1.4	56

#	Article	IF	CITATIONS
415	Characterization of chemically modified steroids for doping control purposes by electrospray ionization tandem mass spectrometry. Journal of Mass Spectrometry, 2005, 40, 494-502.	1.6	71
416	Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. Journal of Mass Spectrometry, 2005, 40, 955-962.	1.6	127
417	Identification of oral antidiabetics and their metabolites in human urine by liquid chromatography/tandem mass spectrometry-a matter for doping control analysis. Rapid Communications in Mass Spectrometry, 2005, 19, 928-936.	1.5	19
418	Mass spectrometry of stanozolol and its analogues using electrospray ionization and collision-induced dissociation with quadrupole-linear ion trap and linear ion trap-orbitrap hybrid mass analyzers. Rapid Communications in Mass Spectrometry, 2005, 19, 3369-3378.	1.5	73
419	Mass Spectrometry in Doping Control Analysis. Current Organic Chemistry, 2005, 9, 825-848.	1.6	43
420	Identification and Characterization of Peptides and Proteins in Doping Control Analysis. Current Proteomics, 2005, 2, 191-208.	0.3	29
421	Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatographyâ^'Tandem Mass Spectrometry for Doping Control Purposes. Analytical Chemistry, 2005, 77, 3579-3585.	6.5	105
422	Electrospray ionization mass spectrometric characterization and quantitation of xanthine derivatives using isotopically labelled analogues: an application for equine doping control analysis. Rapid Communications in Mass Spectrometry, 2004, 18, 1553-1560.	1.5	28
423	N-methyl-N-Trimethylsilyltrifluoroacetamide-Promoted Synthesis and Mass Spectrometric Characterization of Deuterated Ephedrines. European Journal of Mass Spectrometry, 2004, 10, 673-681.	1.0	14
424	Liquid chromatography/electrospray ionization tandem mass spectrometric screening and confirmation methods for β2-agonists in human or equine urine. Journal of Mass Spectrometry, 2003, 38, 1197-1206.	1.6	87
425	Effect of the location of hydrogen abstraction on the fragmentation of diuretics in negative electrospray ionization mass spectrometry. Journal of the American Society for Mass Spectrometry, 2003, 14, 658-670.	2.8	23
426	Doping Control Analysis of Bovine Hemoglobin-Based Oxygen Therapeutics in Human Plasma by LCâ''Electrospray Ionization-MS/MS. Analytical Chemistry, 2003, 75, 3287-3293.	6.5	40
427	Urinary Concentrations of Morphine and Codeine After Consumption of Poppy Seeds. Journal of Analytical Toxicology, 2003, 27, 53-56.	2.8	51
428	Mass Spectrometric Behavior of Thiazide-Based Diuretics after Electrospray Ionization and Collision-Induced Dissociation. Analytical Chemistry, 2002, 74, 3802-3808.	6.5	30
429	Mass spectrometry of steroid glucuronide conjugates. I. Electron impact fragmentation of 5α-/5β-androstan-3α-ol-17-one glucuronides, 5I±-estran-3α-ol-17-one glucuronide and deuterium-labelled analogues. Journal of Mass Spectrometry, 2001, 36, 159-168.	1.6	28
430	Mass spectrometry of steroid glucuronide conjugates. II-Electron impact fragmentation of 3-keto-4-en- and 3-keto-5α-steroid-17-O-β glucuronides and 5α-steroid-3α,17β-diol 3- and 17-glucuronides. Journal of Mass Spectrometry, 2001, 36, 998-1012.	1.6	18
431	High speed determination of beta-receptor blocking agents in human urine by liquid chromatography/tandem mass spectrometry. Biomedical Chromatography, 2001, 15, 393-402.	1.7	56
432	Detection of the plasma volume expander hydroxyethyl starch in human urine. Biomedical Applications, 2000, 744, 345-350.	1.7	40

#	Article	IF	CITATIONS
433	Performance-Enhancing Drugs. , 0, , 283-303.		1